Showing 138 Result(s)

FDA Navigates Workforce Cuts and Political Struggles While Tackling Three Major Challenges in 2026 | STAT

Key Takeaways The FDA is facing significant leadership challenges ahead of 2026. High-profile departures and internal conflicts have lowered employee morale and stability. The future of FDA Commissioner Marty Makary is uncertain, raising concerns among key officials. The Food and Drug Administration, or FDA, is navigating a tricky landscape as it approaches 2026. Recent months …

FDA Voucher Program Has Resulted in Political Overreach in Drug Evaluations, According to Staff Members

Key Takeaways A new FDA program is allowing political influence over drug reviews. Historically, reviews were managed by career scientists to prevent interference. High-ranking officials are involved in deciding which drugs get expedited reviews. This shift raises concerns about the safety and efficacy processes for medications. Introduction The world of pharmaceuticals can be complex, and …

STAT readers on engaging with vaccine skeptics

Understanding the Impact of Anti-Science Rhetoric on Healthcare Key Takeaways Open conversations are crucial between healthcare providers and patients regarding vaccination and treatment. Emotional connections can enhance patient compliance better than data alone. Medical communities must engage in open, respectful discussions on controversial topics. Recognizing and addressing patients’ fears can improve healthcare experiences. The role …

FDA to mandate only one clinical trial for new approvals.

FDA Updates Approval Process: One Clinical Trial Instead of Two In an important shift, the Food and Drug Administration (FDA) plans to change its requirements for medical product approvals. Instead of the usual two clinical trials, the FDA will primarily consider just one trial, as revealed by FDA Commissioner Marty Makary. This change could streamline …

FDA’s New Voucher Initiative Trades Science for Barter System

Key Takeaways: Recent changes at the FDA have raised concerns about the integrity of drug reviews. A new priority voucher program allows accelerated drug approvals but raises ethical questions. Negotiations between drug companies and the administration may compromise scientific standards in drug evaluation. The Changing Landscape of FDA Drug Approvals Recently, there was a shake-up …